Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2020.

Commission File Number 001-36866

 

SUMMIT THERAPEUTICS PLC

(Translation of registrant’s name into English)

 

136a Eastern Avenue

Milton Park, Abingdon

Oxfordshire OX14 4SB

United Kingdom

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F              Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  

---

On July 16, 2020, Summit Therapeutics plc (the “Company”) issued a press release announcing its intention to relocate the corporate domicile of its holding company from the United Kingdom to the State of Delaware in the United States, to be effected by a United Kingdom court-approved scheme of arrangement. The related press release is attached hereto as Exhibit 99.1.

This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-232074).

---

EXHIBIT INDEX

 

Exhibit Number						Description
99.1						Press Release, dated July 16, 2020

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

SUMMIT THERAPEUTICS PLC

Date: July 16, 2020

By:

/s/ Robert W. Duggan

Robert W. Duggan Chief Executive Officer

Chief Executive Officer